The next therapeutic target may already
be in a patient’s blood.
Naturally occurring autoantibodies can alter protein function and, in some patients, are associated with meaningfully different disease trajectories. Seranova profiles these signals to identify human-supported therapeutic hypotheses.
Autoantibodies can reveal drivers of health and disease.
Autoimmunity
8% of patients with rheumatoid arthritis (RA) are reported to generate anti-TNFα autoantibodies. These patients benefit from significantly reduced symptoms (erosions of hands or feet).
Cancer
15% of invasive breast carcinoma patients are reported to produce their own anti-HER2 autoantibodies. Patients with these protective autoantibodies benefit from a significantly higher likelihood of recurrence-free survival.
Neurodegeneration
Healthy individuals commonly produce high-affinity anti-α-synuclein autoantibodies. Patients with Parkinson's and multiple system atrophy (MSA) report significantly lower levels of these protective autoantibodies.
